Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma — Stella
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations(7 sites)
United States
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York
Memorial Sloan Kettering Cancer Center, New York, New York
Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre, New York